Migrén: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CGRP 19
• HMGB1 0
• NOTCH3 0
• GLP-1 0
• MAPK 0
• PI3K 0
• IL-17 0
• IL-6 1
• TNF 1
• PPAR 0
• TREM2 0
• COX-2 0
• IL-4 0
• STING 0
• AKT 0
• AMPK 0
• AQP4 0
• ERK 0
• GIP 0
• GPX4 0
• HIF-1 0
• IL-1 1
• mTOR 0
• NLRP3 0
• NMDA 0
• PD-1 0
• SCN1A 0
• SCN2A 0
• STAT3 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R44

  IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ring

  Mucommune, Llc· Morrisville, Egyesült Államok· 1 163 587 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIA · SB1

  RADIANT: A Pivotal Clinical Study of a Next-Generation Embolic for Chronic Subdural Hematoma

  Arsenal Medical, Inc.· Waltham, Egyesült Államok· 2 238 626 USD awarded in fiscal year 2026· until 2028. máj.

• NIH NINDS · R61

  Generation of a CCL2-CGRP bispecific neutralizing antibody to treat chronic post-traumatic headache

  Washington University· Saint Louis, Egyesült Államok· 816 375 USD awarded in fiscal year 2026· until 2028. febr.

• NIH NINR · K99

  Leveraging Nurses to Improve Care for Postural Orthostatic Tachycardia Syndrome

  New York University School of Medicine· New York, Egyesült Államok· 133 547 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NLM · R21

  Artificial intelligence-enhanced prediction of neuropeptides

  University of Illinois at Urbana-Champaign· Champaign, Egyesült Államok· 210 258 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-JU-IA

  closed-loop IMPlantable tHerapeutic neurOmodulation systems enabled by advanced micRoelectronics and Innovative pAckaging (IMPHORIA)

  Salvia Bioelectronics Bv· Eindhoven, Hollandia· EU contribution 4 567 844 EUR· until 2029. ápr.· 5 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Hospital@Home: Person-centered Digital Transformation for Integrated Home Care (HospitalAtHome)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 14 179 766 EUR· until 2030. dec.· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Combinatorial use of cannabidiol and the serine hydrolase inhibitor AKU-005 to enhance endocannabinoids for treatment of migraine (Migraine cannabinoid)

  King's College London· London, Egyesült Királyság· EU contribution 454 103 EUR· until 2028. jún.· 2 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  INNOVATIVE SOLUTION OF ELECTRO-FOCUS EYEGLASSES (I-SEE)

  Laclaree· Lyon, Franciaország· EU contribution 2 499 999 EUR· until 2026. nov.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders (MECHPAIN)

  Zentralinstitut Fuer Seelische Gesundheit· Mannheim, Németország· EU contribution 2 424 481 EUR· until 2029. szept.

  The disease is named only in the funder's project summary, not in the title.

10 of 329 running projects, newest first. Listed amounts together: 208,8 M USD + 26,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 33
• Gene Expression Profiling 8
• Sequence Analysis, RNA 2
• Exome Sequencing 5
• Proteomics 6
• Metabolomics 6
• Mass Spectrometry 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 137
• Machine Learning 32
• Deep Learning 1
• Cohort Studies 82
• Genome-Wide Association Study 40

• Telomere length as a systemic aging-related susceptibility marker for trigeminal neuralgia: Genetic evidence from mendelian randomization.

  Mol Pain, 2026. nov.

• Integrative genetic analysis identifies shared regulation of DNA methylation and gene expression in migraine risk.

  J Headache Pain, 2026. júl.

• Migraine immune cell gene targets and their relationship to psychiatric disorders.

  J Headache Pain, 2026. júl.

• Genetic regulation of cell type-specific chromatin accessibility contributes to migraine etiology.

  J Headache Pain, 2026. júl.

• Migraine is not a risk factor for glaucoma: Evidence from a bidirectional Mendelian randomization study.

  Medicine (Baltimore), 2026. jún.

• Dissecting the shared genetic architecture between migraine subtypes and cardiovascular diseases: a multi-layered genomic analysis.

  J Headache Pain, 2026. jún.

• Machine Diagnostics and Machine Phenotyping of Migraine: A HUNT Study.

  Neurology, 2026. jún.

• Genome-wide analysis implicates inner ear development in Ménière disease.

  Am J Hum Genet, 2026. jún.

• A phenome-wide association study reveals novel phenotypic determinants of migraine risk in the UK Biobank.

  Headache, 2026. jún.

• Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry.

  Nat Hum Behav, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.